TABLE 2.
Quantitative real-time PCR versus pp65 antigenemiaa
| Method and result type | No. of samples (%) evaluated by pp65 antigenemia assay
|
|||
|---|---|---|---|---|
| Positive | Negativeb | No cells | Total | |
| Quantitative TaqMan PCR (UL125) | ||||
| Positive | 86 | 196 | 10 | 292 (14.8) |
| Negative | 64 | 1,529 | 82 | 1,675 (85.2) |
| Total | 150 (7.6) | 1,725 (87.7) | 92 (4.7) | 1,967 (100) |
| Quantitative TaqMan PCR (UL126) | ||||
| Positive | 111 | 258 | 12 | 381 (19.3) |
| Negative | 39 | 1,480 | 69 | 1,588 (81.7) |
| Total | 150 (7.6) | 1,738 (88.3) | 81 (4.1) | 1,969 (100) |
| Quantitative TaqMan PCR (UL55/UL123-exon 4)c | ||||
| Positive | 122 | 122 | 7 | 251 (12.7) |
| Negative | 29 | 1,629 | 74 | 1,732 (87.3) |
| Total | 151 (7.6) | 1,751 (88.3) | 81 (4.1) | 1,983 (100) |
a
Total number of blood samples: n = 1,983. Testing with UL125 and UL126 was not done in 16 and 14 samples, respectively.
b
Includes 12 samples with indeterminate antigenemia results and 2 samples with inhibited PCR reaction.
c
Testing with double primer (UL55/UL123-exon 4) was only performed in 445 of the samples that showed discrepant results with either antigenemia, culture, or the first run of testing with the UL126 primer.